Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM

Lisanti Capital Growth LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 63,295 shares of the company’s stock, valued at approximately $7,410,000. Mirum Pharmaceuticals comprises approximately 1.6% of Lisanti Capital Growth LLC’s portfolio, making the stock its 8th largest position. Lisanti Capital Growth LLC owned approximately 0.10% of Mirum Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. acquired a new position in Mirum Pharmaceuticals during the 2nd quarter valued at $513,945,000. Janus Henderson Group PLC grew its position in Mirum Pharmaceuticals by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares during the last quarter. State Street Corp increased its holdings in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares during the period. Wellington Management Group LLP raised its position in shares of Mirum Pharmaceuticals by 566.8% during the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after buying an additional 672,118 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Mirum Pharmaceuticals during the second quarter valued at about $78,434,000.

Analyst Upgrades and Downgrades

MIRM has been the subject of a number of research reports. Citizens Jmp reduced their price objective on Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a research report on Thursday, August 6th. Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday. Morgan Stanley set a $137.00 price target on Mirum Pharmaceuticals in a research report on Thursday, August 6th. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 6th. Finally, Wolfe Research initiated coverage on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $137.33.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $102.24 on Thursday. The stock’s fifty day moving average is $111.31 and its 200-day moving average is $102.02. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The stock has a market capitalization of $6.64 billion, a PE ratio of -7.03 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 52 week low of $63.23 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analyst estimates of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.12) earnings per share. Equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 EPS for the current fiscal year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the sale, the chief financial officer owned 36,355 shares in the company, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the transaction, the senior vice president directly owned 1,274 shares of the company’s stock, valued at approximately $127,400. This represents a 96.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 133,156 shares of company stock worth $13,763,562. 8.32% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.